Nano-X Imaging CEO and Directors Report Open-Market Share Purchases
September 30, 2026
Nano-X Imaging Ltd. (NASDAQ: NNOX) today announced that recent SEC Form 4 filings disclosed open-market purchases of the company’s ordinary shares by Chief Executive Officer Erez Meltzer and Board Director Dan Suesskind. These purchases are in addition to other open-market purchases of Nano-X ordinary shares by company insiders including Erez Meltzer, Dan Suesskind and Board […]
Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts
September 29, 2026
A CT scan ordered to answer one clinical question may capture additional anatomical information beyond the original indication. In certain cases, routine CT imaging can include information related to the spine, coronary arteries, liver and other areas, creating an opportunity to support clinical evaluation of findings that may otherwise go unnoticed. Vertebral fragility fractures illustrate […]
Nanox’s Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics
September 25, 2026
Nano-X Imaging Ltd. (NASDAQ: NNOX) is approaching that problem from a different direction. Rather than building another high-end system for major hospitals, Nanox is assembling an integrated platform intended to extend medical imaging into outpatient facilities, clinics and other settings where conventional advanced imaging infrastructure is difficult to justify. Nanox.ARC: Expanding Access to 3D Imaging […]
InvestorNewsBreaks – Nano-X Imaging Ltd. (NASDAQ: NNOX) Is Building End-to-End Platform for the Future of Medical Imaging
September 18, 2026
Nanox (NASDAQ: NNOX) is positioning itself as an integrated medical imaging and healthcare technology company, combining proprietary digital X-ray hardware, FDA-cleared AI applications, cloud software, teleradiology, and healthcare IT into an end-to-end platform designed to support earlier disease detection and more efficient care. Its ecosystem includes Nanox.ARC and the next-generation Nanox.ARC X imaging systems, Nanox.AI […]
InvestorNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Nanox.ARC Distribution Agreement for Costa Rica
September 11, 2026
Nanox (NASDAQ: NNOX) announced a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. SOLME will oversee marketing, distribution, installation, training and ongoing technical support in Costa Rica, where it is a registered supplier […]
InvestorNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Expands Nanox.ARC Distribution in New England
September 4, 2026
Nanox (NASDAQ: NNOX), through its U.S.-based subsidiary Nanox Impact Inc., entered into a distribution agreement with Associated X-Ray Imaging Corp. to support deployment of the Nanox.ARC across New England. Under the agreement, Associated X-Ray Imaging will market, distribute and support the FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its regional customer relationships and service infrastructure. […]
InvestorNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) to Report Second-Quarter 2026 Financial Results Sept. 9
August 26, 2026
Nanox (NASDAQ: NNOX), an innovative medical imaging technology company, announced it will report financial results for the quarter ended June 30, 2026, before market open on Sept. 9, 2026. CEO and Acting Chairman Erez Meltzer and CFO Guy Nathanzon will host a conference call beginning at 8:30 a.m. ET to review the results and provide […]
Nano-X Imaging Ltd. (NASDAQ: NNOX) Is ‘One to Watch’
August 25, 2026
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to […]
InvestorNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Exclusive UK Reseller Agreement for HealthOST AI Bone Solution
August 18, 2026
Nanox (NASDAQ: NNOX), a leader in innovative medical imaging technology, announced that subsidiary Nanox AI Ltd. entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its Nanox.AI bone solution, HealthOST, in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the UK, subject to minimum annual license commitments, for an initial three-year term. HealthOST is an FDA-cleared and UKCA/CE-marked AI […]
InvestorNewsBreaks – Nano-X Imaging Ltd. (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors
August 11, 2026
Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that subsidiary Nanox AI Ltd. has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel OpenVINO toolkit. The framework is designed to enable healthcare facilities to evaluate and deploy CT imaging AI applications on on-premise edge devices while keeping imaging data within their own infrastructure. Nanox.AI solutions analyze routine CT scans to help identify findings correlated […]
InvestorNewsBreaks – NANO-X IMAGING LTD (NASDAQ: NNOX) Announces $8 Million Registered Direct Offering
August 6, 2026
NANO-X IMAGING (NASDAQ: NNOX) announced a securities purchase agreement with a single long-term institutional investor for a registered direct offering expected to generate approximately $8 million in gross proceeds before fees and expenses. The financing includes the sale of 8 million ordinary shares, or prefunded warrants in lieu thereof, together with warrants to purchase up […]
InvestorNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Spotlighted in BioMedWire Editorial on AI-Driven Impairment Detection
May 13, 2026
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in BioMedWire editorial coverage highlighting the growing demand for real-time, noninvasive impairment detection technologies, with the company positioned as a differentiated player leveraging artificial intelligence and voice analysis to […]
InvestorNewsBreaks – Nano-X Imaging Ltd. (NASDAQ: NNOX) Announces $15 Million Registered Direct Offering
November 26, 2025
Nano-X Imaging (NASDAQ: NNOX) entered a securities purchase agreement with a single institutional investor to sell 3,826,530 ordinary shares in a registered direct offering expected to generate approximately $15 million in gross proceeds, with Titan Partners Group, a division of American Capital Partners, serving as sole placement agent. Closing is expected on or about Nov. […]
ROTH to Host 14th Annual Technology Conference at the Hard Rock Hotel in New York City
November 12, 2025
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — via IBN — Roth Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 14th Annual Roth Technology Conference on November 18-19, 2025, at the Hard Rock Hotel, 159 W 48th St, New York, NY 10036. The conference will provide pre-qualified institutional investors with the opportunity to […]
IBN Announces Latest Episode of The Stock2Me Podcast featuring Mike Larson, Editor-in-Chief at MoneyShow
October 4, 2024
LOS ANGELES, Oct. 04, 2024 (GLOBE NEWSWIRE) — IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating array […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Recent Research Report by Zacks SCR
May 3, 2023
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) (https://ibn.fm/XI5mO). The report considers the potential approval and commercialization of products processed with the company’s patented DehydraTECH(TM) drug delivery platform technology that increases drug bioavailability, and ongoing research and development (“R&D”) activities, […]
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry
May 11, 2022
Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment Lexaria has also made some significant progress in the use of its […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event
May 3, 2022
Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B In the United States, the company operates the […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Phase of Epilepsy Research Using DehydraTECH(TM)-CBD
March 22, 2022
Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavors The epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulation The global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
November 3, 2021
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
November 1, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of […]